Perception of Cure Among Patients With Metastatic Cancer
NCT ID: NCT04820894
Last Updated: 2025-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2021-10-30
2022-01-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers
NCT05091190
UNC Metastatic Cancer Radiation Therapy Registry
NCT06306924
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
NCT04989725
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
NCT00836992
Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma
NCT07111104
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the proportion of patients with metastatic cancer who anticipate cure before starting immunotherapy.
SECONDARY OBJECTIVES:
I. To determine if expectations of cure are associated with quality of life and distress.
II. To determine if patients' perceptions differ by gender, age, and ethnicity.
OUTLINE:
Patients complete surveys over 30 minutes about sociodemographic information and perception of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety, over 10 minutes about depression, and over 30 minutes about physical well-being. Patients' medical records are reviewed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational (survey, medical records review)
Patients complete surveys over 30 minutes about sociodemographic information and perception of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety, over 10 minutes about depression, and over 30 minutes about physical well-being. Patients' medical records are reviewed.
Electronic Medical Record
Medical records are reviewed
Survey Administration
Complete surveys
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electronic Medical Record
Medical records are reviewed
Survey Administration
Complete surveys
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients must be aged 18 and over
2. Patients sufficiently fluent in English
3. Patients must have a cytologically or pathologically verified diagnosis of cancer
4. Patients must have measurable metastatic disease
5. Patients must be initiating immunotherapy
6. Patients must be undergoing evaluation and treatment at City of Hope Cancer Center
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sumanta K Pal
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2021-01818
Identifier Type: REGISTRY
Identifier Source: secondary_id
19322
Identifier Type: OTHER
Identifier Source: secondary_id
19322
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.